Novozymes A/S Stock

Novozymes A/S Equity

The The Equity of Novozymes A/S (NSIS B.CO) as of Aug 7, 2026 is 11.18 B EUR. In the previous year, The Equity was 1.87 B EUR — a change of 496.97% (higher).

Equity

11.18 BEUR

YoY

496.97%

Last updated:

In 2026, Novozymes A/S's equity was 11.18 B EUR, a 496.97% increase from the 1.87 B EUR equity in the previous year.

Access this data via the Eulerpool API

Novozymes A/S Stock analysis

What does Novozymes A/S do? Novozymes A/S is a leading company in the field of biocatalysis and microbial solutions. It was founded in Denmark in 1925 under the name Nordisk Insulinlaboratorium. In 2000, the company was renamed Novozymes A/S and became part of the globally operating Novo Group. Novozymes' business model is to optimize the use of biocatalysts, enzymes, and microorganisms to offer sustainable solutions for various industries. Biocatalysts are biological molecules that accelerate or enable chemical reactions. The company works closely with customers in agriculture, household, food and beverage, laundry and cleaning products, animal feed, bioenergy, and biopharmaceutical industries. Novozymes' offerings include various divisions. The largest is the enzymes division, which produces enzymes for various industries. Novozymes' enzymes are used in the food and beverage industry, pulp and paper industry, and bioenergy, among others. The microbial solutions division offers various microorganisms that can be used in the production of biogas, animal feed, or odor removal. Novozymes also has a bioagriculture division that develops solutions for sustainable agriculture. This includes disease- and pest-resistant bioseeds, as well as enhanced soil and plant care. The company also has a biopharmaceutical division that focuses on producing enzymes for disease treatment. An important goal of Novozymes is to promote sustainability and environmental protection. The company advocates for the use of renewable resources and energy-efficient processes. This is also reflected in their products, which contribute to optimizing agricultural processes and reducing greenhouse gas emissions, for example. One example of a Novozymes product is NovoGro, a biofertilizer for sustainable agriculture. NovoGro enhances nutrient uptake in plants and contributes to healthy soils. Another product is an enzyme blend called Novozyme 188, which is used in beer production to improve filtration. In summary, Novozymes A/S is a company specializing in biocatalysis and microbial solutions. The company works closely with customers from various industries to offer sustainable solutions and promote environmental protection. Novozymes has different divisions and offers solutions such as enzymes and microorganisms that can be used in the food and beverage industry, pulp and paper industry, bioenergy, biopharmaceuticals, and many other areas. With its commitment to sustainability and environmental protection, Novozymes contributes to shaping a better future. Novozymes A/S is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Novozymes A/S's Equity

Novozymes A/S's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Novozymes A/S's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Novozymes A/S's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Novozymes A/S's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Novozymes A/S’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Novozymes A/S stock

The Equity of Novozymes A/S is 11.18 B EUR in 2026.

The Equity of Novozymes A/S changed from 1.87 B EUR to 11.18 B EUR, representing a 496.97% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Novozymes A/S since 2006 – with annual values, charts, and detailed analysis.

The Equity's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Novozymes A/S historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Novozymes A/S

All Key Metrics — Novozymes A/S